AMETEK, Inc. vs Humana Inc — how do they compare? AMETEK, Inc. trades at $258.81 (market cap $58.76B), while Humana Inc trades at $385.11 (market cap $44.77B). The key difference: AMETEK, Inc. is the larger of the two by market cap, and Humana Inc pays the higher dividend (0.95%). Which is the better fit depends on your goals.
| AME | HUM | |
|---|---|---|
Market Cap | $58.76B | $44.77B |
Sector | Industrials | Health |
52-Week High | $256.30 | $409.42 |
52-Week Low | $179.28 | $163.67 |
Enterprise Value | $60.30B | $52.12B |
Dividend Yield | 0.53% | 0.95% |
Signals from Pluang's Aura AI — not financial advice
AME's stock trades at $257.9, up 1.99% today, reflecting strong momentum after recent earnings beats. The company reported record Q2 2026 results with EPS of $2.09, exceeding estimates, and raised full-year guidance. Valuation metrics like a P/E of 37.47 and P/S of 7.51 are elevated, but supported by robust profitability, including a 20.04% net income margin and 14.56% ROE. Technical indicators show a bullish trend, with the current price near resistance at $258.
The outlook remains positive, driven by consistent earnings growth and strong demand across business segments. Key risks include high valuation multiples and potential economic headwinds. With a consensus price target of $281.86 and no sell ratings from analysts, the stock offers upside potential, but investors should monitor execution against guidance and market volatility.
Humana (HUM) trades at $386.11, up 0.17% today, with a neutral technical outlook and mixed fundamentals. The stock shows strong revenue growth reaching $129.66B in 2025 but faces margin compression with net income margin declining to 0.88%. Recent Q2 2026 earnings beat expectations with EPS of $7.61 versus $7.27 expected, while management focuses on Medicare Advantage margin expansion and cost reductions.
Outlook remains cautiously optimistic with a consensus price target of $409.93 offering 6% upside potential. Key opportunities include Medicare Advantage growth and operational efficiency gains, while risks involve margin pressure, regulatory changes in healthcare, and competitive threats. Analyst sentiment leans neutral with 57% hold ratings amid ongoing business transformation.
Trailing returns across standard periods
Ametek is a diversified industrial conglomerate with over $6 billion in sales. The firm operates through an electronic instruments group and an electromechanical group. EIG designs and manufactures differentiated and advanced instruments for the process, aerospace, power, and industrial end markets. EMG is a focused, niche supplier of highly engineered automation solutions, thermal management systems, specialty metals, and electrical interconnects, among other products. About half of the firm's sales are made in the United States. The firm's asset-light strategy in place for nearly two decades emphasizes growth through acquisitions, new product development through research and development, driving operational efficiencies, and global and market expansion.
Read more on AME →Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →